EMERGE-201: A Phase 2, Multicenter, Open-label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced or Metastatic Solid Tumors

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Feb 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Lurbinectedin (Primary)
Indications Advanced breast cancer; Biliary cancer; Endometrial cancer; Gastric cancer; Lung cancer; Male breast cancer; Neuroendocrine tumours; Oesophageal cancer; Pancreatic cancer; Solid tumours; Urogenital cancer
Focus Therapeutic Use
Acronyms EMERGE-201
Sponsors Jazz Pharmaceuticals plc

23 Feb 2024 Status changed from active, no longer recruiting to completed.
29 Jan 2024 According to pharmar media release, the data from this study presented at the ASCO Genitourinary Cancers symposium that has been held from the 25th to 27th of January in San Francisco, USA.
29 Jan 2024 Results published in the PharmaMar Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com